Sr Director Portfolio & Strategic Planning and Corporate Developmemt
ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company
Responsibilities included providing strategic direction to upper management including Go/No-Go decisions, strategic recommendations, M&A options, Unbiased Sharpe portfolio, Clinical Development Plans and Hedge Risk Strategies. Additional responsibilities include developing relationships with key opinion leaders in clinical, medical and academia.
Develop and maintain ownership for commercial and scientific expertise of key therapeutic areas. Spearhead investigations of therapeutic areas new to ImClone and develop recommendations for market entry. Build the vision for what markets might look like five to ten years in the future, including how changes in diagnostics, clinical guidelines, and new therapies, will shape the landscape. Review market research and facilitate the group's ability to project future marketplace dynamics and future product or company licensing opportunities. Develop new tools for group to use in assessing markets and forecasting new opportunities.
Identify alternative strategies, quantifying risks, and forecasting product sales and profits under various scenarios. Present strategic options and recommendations to licensing project team and senior management.